The Problem: Finding Needles in High-Dimensional Haystacks
Precision medicine depends on robust biomarkers, but finding them is extraordinarily difficult. A single tumor biopsy yields expression data for 20,000+ genes, millions of methylation sites, and thousands of proteins. Traditional statistical approaches — constrained by multiple testing corrections and linear assumptions — fail to capture the complex, non-linear relationships that define biological systems. The companion diagnostics market exceeds $6 billion and grows at 12% annually, creating enormous pressure to discover and validate predictive biomarkers faster.
The Solution: Multi-Omics ML Pipelines
Modern ML approaches leverage complementary algorithm families. Random forests provide robust feature importance rankings. Deep learning autoencoders compress high-dimensional data into latent representations capturing non-linear relationships. Multi-omics integration learns joint representations across genomic, proteomic, and metabolomic data — capturing cross-omic interactions that single-omic analyses miss entirely. A Swiss diagnostics firm used this approach to identify a 12-gene signature predictive of pembrolizumab response in NSCLC, validated across 1,200 patients with AUC of 0.89 versus 0.71 for PD-L1 alone.
The Approach: From Discovery Through Regulatory Approval
- IVDR compliance pathway for EU market access, including Annex XIII clinical evidence requirements
- Swissmedic alignment through mutual recognition and parallel assessment
- FDA expectations for AI/ML-based Software as a Medical Device (SaMD) transparency
- Prospective clinical validation study design aligned with CLSI EP28-A3c
How ANG Associates Can Help
ANG Associates guides diagnostics and pharma companies through the complete biomarker discovery-to-market journey. We provide AI strategy for ML pipeline design, project management for cross-functional biomarker programs spanning R&D, regulatory, and commercial, and IT delivery management for the data infrastructure required to support multi-omics analytics. Our regulatory knowledge ensures your AI-based companion diagnostic program is built for approval from day one.